Synthetic lethal targeting of lobular breast cancer
The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell. However, the loss of these genes is predicted to create vulnerabilities in the cancer cell that can nevertheless be targeted with drugs. We have compelling data showing that the loss the tumour suppressor gene CDH1, an event that is a hallmark the lobular subtype of breast cancer, creates vulnerabilities which can be targeted with drugs. In this project, we will develop new breast cancer treatments which exploit these vulnerabilities.
Keep reading
View all
Can Functional MRI of the Brain help us understand Brain Fog in Women with Breast Cancer?
Up to 70% of women with breast cancer experience cognitive difficulties, but scientists still don't fully understand why this happens. Without a clear understanding of the underlying cause, it is d...
Exploring Better Breast Imaging for Women in Aotearoa New Zealand
Mammograms save lives by finding breast cancer early. But they do not work equally well for everyone.For women with very dense breast tissue, cancer can be harder to see on a standard mammogram. Th...
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can face delay...
